21:40 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

CFDA approves EGFR TKI companion diagnostic

Amoy Diagnostics Co. Ltd. (SZSE:300685) said China FDA approved the Super-ARMS EGFR Mutation Test as a companion diagnostic for EGFR tyrosine kinase inhibitor (TKI) therapies, including Iressa gefitinib and Tagrisso osimertinib from AstraZeneca plc (LSE:AZN;...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Company News

Amoy Diagnostics, Merck KGaA deal

Merck and Amoy partnered to develop and commercialize a liquid biopsy biomarker test that will assess Ras mutation status in patients with colorectal cancer. The test will use Amoy’s ADx-SuperARMS real-time PCR technology. Amoy plans...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Company News

Amoy Diagnostics, Illumina deal

Amoy will develop and commercialize oncology related tests based on Illumina’s next-generation sequencing (NGS) technology, including TruSight Tumor 15, in China. TruSight Tumor 15 is an NGS-based test that offers a comprehensive assessment of 15...